Warren, R.; Reich, K.; Simpson, E.; Langley, R.; Costanzo, A. .; Saeki, H.; Almgren, P.; Vacko, E.; Carlsson, A.; Gooderham, M.; Deleuran, M.; Silvestre, J. F.; Weidinger, S.; Blauvelt, A. 3 Years of Tralokinumab Treatment Provides Long Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Modera Te to Severe Atopic Dermatitis. J of Skin 2023, 7, s142.